

ENCALS

European Network to Cure ALS

**ENCALS MEETING 2026
MADRID • SPAIN**

24-25-26 JUNE 2026

PRE-CONGRESS DAY: JUNE 23

www.encals-congress.com



FINAL PROGRAM



INDEX

FIRST SECTION

Welcome letter	03
Venue	04
Main Contact details	04

Committees

ENCALS Executive Board	05
Speakers	06

SCIENTIFIC PROGRAM

Scientific Grid

Pre-Congress	08
Congress	09-11

Program

Tuesday (Pre-Congress)	12
Wednesday (Congress)	16
Thursday (Congress)	20
Friday (Congress)	25

SECOND SECTION

Industry Sponsored session

Tuesday 14.00-16.30h (Go to page - click here)	27
Wednesday 11.45-13.00h (Go to page - click here)	28
Wednesday 11.30-13.00h (Go to page - click here)	29
	30
	30



WELCOME LETTER

Dear colleagues and partners,

On behalf of the ENCALS Executive Board and the Organizing Committee ENCALS Madrid 2026, it is our pleasure to welcoming you to the Annual Meeting of the European Network for the Cure of ALS, which is taking place in Madrid, from June 23rd to 26th, 2026, at the Palacio Municipal de Congresos.

ENCALS is the leading European forum for researchers, clinicians, and professionals dedicated to the study of amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Each year, this meeting brings together the most active and innovative teams in the field to share scientific discoveries, foster collaboration, and accelerate the translation of knowledge into meaningful therapeutic advances.

Madrid is hosting more than 1.000 researchers, neurologists, clinical teams and healthcare professionals during ENCALS 2026, presenting the latest progress in genetics, molecular biology, biomarkers, neuroimaging, clinical trials, technological innovation, and multidisciplinary care.

We would like to thank all the companies participating in ENCALS 2026. Your support is essential to make this event possible, and your participation directly contributes to both scientific progress and social impact in the fight against ALS.

With our warmest regards,

Leonard van den Berg and Orla Hardiman
on behalf of the ENCALS Executive Committee

Alberto García Redondo and Jesús Esteban Pérez
on behalf of the Organizing Committee ENCALS Madrid 2026

VENUE



PALACIO MUNICIPAL DE CONGRESOS DE MADRID (PALACIO MUNICIPAL - IFEMA MADRID)

Av. Capital de España, 7, 28042 Madrid (Spain)

[Website - click here](#)



The IFEMA Palacio Municipal in Madrid, Spain, is a modern and versatile convention center known for hosting a wide range of events, conferences, and exhibitions. Conveniently located near the city center, it offers state-of-the-art facilities and easy access to transportation, making it a prime venue for international gatherings.



MAIN CONTACT DETAILS

ENCALS HEADQUARTERS

P.O box 85500
3508 GA Utrecht
The Netherlands
info@encals.eu
www.encals.eu

ENCALS

European Network to Cure ALS

TORRESPARDO Association Management

ENCALS 2026 TECHNICAL SECRETARIAT

Registration Manager
Carolina Rovira
registration@torrespardo.com

Scientific Manager
Desirée Muñoz
d.munoz@torrespardo.com

Sponsorship Manager
Miss Asun Marzo
a.marzo@torrespardo.com

COMMITTEES

ENCALS Executive board

Chair:

Leonard van den Berg
(The Netherlands)

Co-chair:

Orla Hardiman
(Ireland)

Treasurer:

Adriano Chio
(Italy)

Caroline Ingre
(Sweden)

Philip van Damme
(Belgium)

Markus Weber
(Switzerland)

Monica Povedano
(Spain)

Peter Andersen
(Sweden)

Francois Salachas
(France)

Magdalena Kuzma
(Poland)

Sharon Abrahams
(Scotland)

Julian Grosskreutz
(Germany)

Ammar Al-Chalabi, chair award committee
(England)

Thomas Meyer
(Germany)

Vincenzo Silani
(Italy)

Philippe Corcia
(France)

Blaž Kortnik
(Slovenia)

Martin Turner
(England)

Christopher McDermot
(England)

SPEAKERS



Prof. Ammar Al-Chalabi

Maurice Wohl Clinical Neuroscience Institute
King's College London
London, United Kingdom



Prof. Andrea Calvo

Università degli Studi di Torino
AOU Città della Salute e della Scienza
di Torino Hospital
Turin, Italy



Dr. Alejandro Caravaca Puchades

Hospital Universitari de Bellvitge - IDIBELL
Barcelona, Spain



Prof. John Landers

UMass Medical School
Worcester, MA, USA



Dr. Mónica Povedano Panadés

Hospital Universitari de Bellvitge - IDIBELL
Barcelona, Spain



Dr. Teresa Salas Campos

Hospital Universitario La Paz/Carlos III
Madrid, Spain



Dr. Alexander Thompson

University of Oxford
Oxford, United Kingdom



Prof. Nicola Ticozzi

Istituto Auxologico Italiano, University of Milan
Milan, Italy



Dr. Ruben van Eijk

University Medical Center Utrecht
Utrecht, The Netherlands



Prof. Christine Vande Velde

Université de Montréal
Montreal, Canada



Prof. Jochen Weishaupt

Universitäts und Rehabilitationskliniken Ulm
(RKU)

Ulm, Germany

ENCALS

European Network to Cure ALS

SCIENTIFIC PROGRAM



Scientific Grid Pre-Congress Day

TUESDAY June 23rd

	FIRST FLOOR		SECOND FLOOR		FOURTH FLOOR
	BUENOS AIRES - HAVANA - MEXICO ROOM	PRENSA ROOM	CARACAS - BOGOTÁ ROOM	LA PAZ - MONTEVIDEO ROOM	BRATISLAVA ROOM
09:00-10:00					
10:00-11:00		INARC MEETING			
11:00-12:00					
12:00-13:00				PRECISION ALS	
13:00-14:00	Break				premodiALS Consortium
14:00-15:00	Industry session (see page 9)	INARC MEETING			
15:00-16:00			ALS App Europe Initiative	PRECISION ALS	
16:00-17:00					Asymptomatic Gene Carrier Studies
17:00-18:00					

WEDNESDAY June 24th

	FIRST FLOOR		SECOND FLOOR		FOURTH FLOOR
	BUENOS AIRES - HAVANA - MEXICO ROOM	PRENSA ROOM	CARACAS - BOGOTÁ ROOM	LA PAZ - MONTEVIDEO ROOM	BRATISLAVA ROOM
09:00-10:00	(09.00-11.45) TRICALS	Neuropsychology workshop		SEED Consortium	
10:00-11:00					
11:00-12:00					
12:00-13:00	(11.45 - 13.00) Industry session (see page 15)		(11.30 - 13.00) Industry session (see page 16)		

Scientific Grid

ENCALS Meeting

WEDNESDAY June 24th

	AUDITORIUM
13:00-13:30	WELCOME ADDRESS
13:30-15:00	GENETICS AND GENOMICS IN ALS: FROM DISCOVERY TO PRECISION THERAPIES Plenary Speaker: John Landers (Worcester, MA, United States)
15:00-15:30	Coffee break and posters
15:30-17:00	PRESYMPTOMATIC & BIOMARKERS Plenary Speaker: Alex Thompson (Oxford, United Kingdom)
17:00-17:20	RAPID FIRE PRESENTATIONS
17:20-19:00	ENCALS RESEARCH FORUM – POSTERS SESSION

Scientific Grid

ENCALS Meeting

THURSDAY June 25th

	AUDITORIUM
08:30-10:00	INNOVATIVE PRECLINICAL MODELS: BRIDGING MECHANISMS AND TRANSLATION Plenary Speaker: Jochen Weishaupt (Ulm, Germany)
10:00-10:25	Coffee break and posters
10:25-10:30	Group photo
10:30-11:40	EPIDEMIOLOGY AND PHENOTYPING Plenary Speaker: Mónica Povedano Panadés (Barcelona, Spain)
11:40-12:30	DEBATE: ARE WE READY TO REDEFINE ALS THROUGH PRECISION AND EARLY INTERVENTION? Speakers: Andrea Calvo (Turin, Italy) and Ammar Al-Chalabi (London, United Kingdom)
12:30-12:50	RAPID FIRE PRESENTATIONS
12:50-13:50	Lunch time and posters
13:50-14:50	ALS AS A MULTISYSTEM DISORDER: BEYOND MOTOR NEURON DEGENERATION Plenary Speaker: Teresa Salas Campos (Madrid, Spain)
14:50-15:15	RAPID FIRE PRESENTATIONS
15:15-15:45	Coffee break and posters
15:45-17:00	RETHINKING ALS PATHOGENESIS: EMERGING MOLECULAR PARADIGMS Plenary Speaker: Christine Vande Velde (Montreal, Canada)

20:00	NETWORKING DINNER (Not included in the registration fee)
-------	---

Scientific Grid

ENCALS Meeting

FRIDAY June 26th

	AUDITORIUM
09:00-10:15	CLINICAL TRIALS, STRATIFICATION AND CLINICAL OUTCOMES Plenary Speaker: Ruben van Eijk (Utrecht, The Netherlands)
10:15-10:45	YOUNG INVESTIGATOR AWARD
10:15-11:15	Coffee break
11:15-12:45	ADVANCED CLINICAL PHENOTYPING USING NEW TECHNOLOGIES Plenary Speakers: Alejandro Caravaca Puchades (Barcelona, Spain) and Nicola Ticozzi (Milan, Italy)

Tuesday June 23th - Pre-Congress

INTERNATIONAL NETWORK FOR ALS - RESEARCH AND CARE (INARC)

Tuesday, June 23th

09.30-16.45

Prensa room

Please note that this is a closed meeting. Prior registration is mandatory for attendance. We cannot accommodate walk-ins.

Please contact inarc@tricals.org for questions about this meeting.

PERSON-CENTRED APPROACHES TO CARE AND RESEARCH FOR PEOPLE WITH MND/ALS

09.30-09.45 **Welcome and introduction to the day**

09:45-11:00 THE HOLISTIC APPROACH: ENSURING OPTIMAL AND APPROPRIATE PRACTICE

Fouke Ombelet ALS/MND Nurse Specialist,

KU Leuven Center for Brain & Disease Research

Explore MDT roles, ethical considerations, and contextual factors that support patient-centred decisions

11:00-11:30 Coffee Break

11:30-12:30 COMMUNICATING EFFECTIVELY ABOUT RESEARCH WITH PEOPLE WITH AND AFFECTED BY MND

Michaela Waltho, Clinical Nurse Specialist,

National Hospital for Neurology and Neurosurgery, London

Investigate empathic, professional communication in emotionally challenging situations, focusing on what patients need to feel heard and understood.

Scenarios include disease progression, delivering bad news, and trial ineligibility.

12:30-13:15 Lunch

13:15-14:15 RESPIRATORY SYSTEMS – A HANDS-ON WORKSHOP

Saúl Marín Esteban, Physiotherapist and Clinical Trial Coordinator.

La Paz University Hospital

Paul Matthew Burnham, Specialist Respiratory Physiotherapist.

Gregorio Marañón Hospital.

Miguel Valdazo Alonso, Respiratory Physiotherapist.

Breas Medical

Pilar Carbajo Gullón, Clinical Trials Research Nurse.

La Paz University Hospital

This interactive session introduces respiratory devices, SNIP, FVC and peak flow, and their use in research.

Tuesday June 23th - Pre-Congress

14:15-15:00 COGNITIVE AND BEHAVIOURAL CHANGE: PROVIDING GOOD CARE & ENABLING RESEARCH PARTICIPATION WHEN THESE ARE PRESENT

Professor Eneida Mioshi, University of East Anglia

This session will present current evidence while exploring experiences of those involved in care and research recruitment when cognitive and behavioural changes are present. We will share some potential parameters to support care and research participation practices across all affected by MND/ALS.

15:00-15:15 Comfort break

15:15-16:30 PRACTICAL CHALLENGES IN MND RESEARCH

Alizé Chalançon, Project Manager, National Clinical Research Network France.

In this session you will share the launch of the new Start Up package – a guide to setting up clinical trials.

16:30-16:45 Evaluation of the day

ALS APP EUROPE INITIATIVE MEETING

Tuesday, June 23th

15:00-18:00

Caracas-Bogotá Room

15.00-15.15 Welcome coffee

15.15-15.45 Revised self-explanatory ALSFRS-R

15.45-16.15 Introduction of ALS Center App

16.15-16.45 Coffee break

16.45-17.30 ALS-OPM classification: correlation with ALS progression, NfL and survival

17.30-18.00 ALS-OPM in multiple languages

Tuesday June 23th - Pre-Congress

PRECISION ALS

Tuesday, June 23th

12.00-18.00

La Paz -Montevideo room

12.00-12:30 Lunch and Registration

12.30-12.45 Introduction to the Largest ALS Dataset in the World

12.45-13.45 PRECISION ALS Platform

Ronan McDonnell and the Technical Team

13.45-14.15 Discussion

14.15-14.30 Data Harmonisation, Update and Progress

14.30-15.00 Biomarkers: Neurofilaments, Proteomics, Transcriptomics

15.00-15.15 Discussion

15.15-15.30 Coffee

15.30-15.45 Digital Health Technologies

Marc Elliot

15.45-16.15 Social Determinants of Health

Miriam Galvin

16.15-16.45 AI & Machine Learning

Robert Ross

16.45-17.30 Discussion and Next Steps

17.30-17:50 Summary and Date for the Next Meeting

Tuesday June 23th - Pre-Congress

PREMODIALS

Tuesday, June 23th

13.00-15.30

Bratislava room

- | | |
|-------|--|
| 13:00 | Welcome and Introduction
(Lingor)
State of the analysis and plan of future analysis |
| 13:05 | Overview of current analysis
(Tzeplaeff / Lingor / Galhoz / Menden) |
| 13:20 | Future analyses
Speech analysis – Ki-elements
(Thies)
miRNA analysis
(Magen / Hornstein)
Cell free DNA analysis
(Lingor) |
| 13:40 | Predicting Phenoconversion to Clinically Manifest ALS
(Benatar) |
| 13:55 | Discussion on the stage of the data, plans, publication strategies
(all)
Ongoing and future Recruitment |
| 14:15 | Overview of the international recruitment
France - Tours (Corcia)
Slovakia (Turčanová)
Turkiye - Antalya (Uysal)
Switzerland (Weber / Neuwirth)
Israel (Lerner / Alhlim)
Czech Republic (Vlčková / Betík)
Germany - Rostock (Hermann)
Germany - Munich (Lingor) |
| 14:45 | Presentation of the new recruitment centers
France (Couratier / Guy / Danel Brunaud / del Mar Amador / Soriani / Bernard)
Turkiye - Istanbul (Ofłazer)
Spain (Rubio)
Belgium (Masroni) |
| 15:00 | Discussion on recruitment planning and goals (all)
Future of premodiALS – how to maintain a sustainable structure? |
| 15:20 | Prolongation of premodiALS and novel opportunities
(Lingor / all) |
| 15:30 | End of the official meeting |

Wednesday June 24th - Congress

TRICALS

Wednesday, June 24th

08.15-11.50

Buenos Aires – Havana – Mexico room

Insights in recent and current clinical trial results

During the TRICALS satellite meeting, Companies will present their trial results, and several companies will provide updates on their ongoing studies. There will be ample opportunity for questions and discussion. This meeting represents an important moment to showcase the current state of clinical research in ALS and to highlight what lies ahead.

- 08:15-08:45 Breakfast, networking and walk-in
- 08:45-09:00 Opening by Prof. Leonard van den Berg
- 09:00-10:00 Study results: Magnet lithium, Quralis, argenx, AL-S pharma, Corcept, Neurosense
- 10:00-10:15 Bio break
- 10:15-11:05 Study updates: VectorY, Leal Therapeutics Inc., Axoltis, Ionis, Trace Neuroscience, Zydus Therapeutics Inc., NuraBio, Eli Lilly, ProjenX
- 11:05-11:30 Panel discussion with Group 2 presenters
- 11:30-11:50 PREVAiLS study update

NEUROPSYCHOLOGY WORKING GROUP

Wednesday, June 24th

09.00-12.30

Prensa room

Findings from last year

Joke De Vocht

Introduction to this year's theme

Ratko Radakovic, Caroline McHutchison

Talks from young researchers

[TBD]

Interactive session: Understanding Behaviour in ALS

Ratko Radakovic, Caroline McHutchison

Wednesday June 24th - Congress

SEED-ALS

Wednesday, June 24th

09.00-11.30

La Paz - Montevideo Room

09:00-09:05 **Welcome**

Carlos Sanz

09:05-09:20 **PROJECT UPDATE**

Economic data

Carlos Sanz

General section

Adolfo López de Munain

Registry

Carmen Paradas

09:20-10:00 **CLINICAL CORE**

Carmen Paradas

10:00-10:30 **BASIC CORE**

Cellular

Ana Martínez

Lipidomics and metabolism

Estela Área

Cellular

Sonia Alonso

10:30-11:30 **Questions and discussion /
Q&A session**



Wednesday June 24th - Congress

13:00-13:30 WELCOME ADDRESS

13:30-15:00 GENETICS AND GENOMICS IN ALS

Moderators:

Wouter van Rheenen (University Medical Center Utrecht, The Netherlands)

Juan Francisco Vázquez Costa (Hospital Univ. La Fe, Valencia, Spain)

13:30-13:45 Plenary Speaker:

John Landers (UMass Medical School, Worcester, MA, United States)

13:45-13:50 Discussion

13:50-14:00 Analysis Of ARPP21 Mutations In Familial And Sporadic Amyotrophic Lateral Sclerosis In The Spanish Population

Álvaro Carbayo Viejo, Spain

14:00-14:10 Rare Pathogenic Neurologic And Neurodevelopmental Variants In Als Associate With Onset, Survival And Family History

Ciara O'Donoghue, Ireland

14:10-14:20 Using Dutch Archive Data To Reconstruct Als Superpedigrees At Scale

Daphne van Oosten, The Netherlands

14:20-14:30 The Shared And Differential Genetic Risk Factors Of Neurodegeneration

Tomas Gomes, Ireland

14:30-14:40 U7 SnRNAs Based Gene Therapies Targeting Cryptic Splicing Events Involved In ALS/FTD

Alessandro Marrero Gagliardi, United Kingdom

14:40-14:50 Restoring TDP-43 Function: The Translational Potential Of AP-2 In ALS

Ana Martinez, Spain

14:50-15:00 Arc-Mediated TDP-43 Encapsidation Drives Intercellular Propagation In ALS: A Novel Therapeutic "Firewall" Validated By Lenacapavir Repositioning

Gorka Gereñu Lopetegí, Spain

15:00-15:30 Coffee Break and Posters

15:30-17:00 PRESYMPTOMATIC & BIOMARKERS

Moderators:

Jenna Gregory (Institute of Medical Sciences, University of Aberdeen, United Kingdom)

Miguel Ángel Rubio Pérez (Hospital del Mar, Barcelona, Spain)

15:30-15:45 Plenary Speaker:

Alexander Thompson (University of Oxford, Oxford, United Kingdom)

15:45-15:50 Discussion

15:50-16:00 Presymptomatic Changes In Brain Structure In Sporadic And C9orf72 Mutation Carrying ALS Patients

Pauline van Lieshout, The Netherlands

16:00-16:10 Plasma Lipidomic Signatures Contribute To Biological Stratification Of ALS Progression

Bernat Bertran Recasens, Spain

Wednesday June 24th - Congress

- 16:10-16:20 **A Large Scale Study Of Urinary P75ECD In Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis And Mimics**
Koen C. Demaegd, The Netherlands
- 16:20-16:30 **Muscle Proteins Dominate The Circulating Proteomic Signature Of ALS And ALS Phenotypes**
Louisa Azizi, Sweden
- 16:30-16:40 **Sweat Gland TDP-43 Pathology Precedes Symptom Onset In Amyotrophic Lateral Sclerosis**
Katie Hanna, United Kingdom
- 16:40-16:50 **Lipid And Muscle Biomarker Trajectories Before ALS Or FTD**
Christos V. Chalitsios, United Kingdom
- 16:50-17:00 **Multiparametric Muscle Ultrasound In Early Amyotrophic Lateral Sclerosis: Morphological And Textural Biomarkers As Diagnostic Discriminators**
José Ríos-Díaz, Spain

17:00-17:20 RAPID FIRE PRESENTATIONS

Moderators:

Magdalena Kuzma-Kozakiewicz (Medical University of Warsaw, Poland)

Janne M. Toivonen (Univ. Zaragoza, Spain)

- 17:00-17:02 **Different Contribution Of Nucleus Accumbens And Amygdala Subnuclei To The Emergence Of Positive And Negative Behavioural Symptoms In Amyotrophic Lateral Sclerosis**
Alessio Maranzano, Italy
- 17:02-17:04 **Spinal Cord Atrophy Across Clinical Phenotypes And Stages In Amyotrophic Lateral Sclerosis: Results From a large multicentre MRI Cohort**
Giorgia Querin, France
- 17:04-17:06 **The Effect Of An UNC13A Polymorphism On Neuroimaging In ALS**
Justus van Nispen tot Sevenaer, The Netherlands
- 17:06-17:08 **Quantifying Survival Differences Between ALS Clinical Trial Participants And Population Cohorts: Evidence of prognostic enrichment in clinical trials**
Emeka Uzochukwu, United Kingdom
- 17:08-17:10 **Replication Of Beta EEG Oscillations Related To The Sustained Attention To Response Task In Irish And Dutch Cohorts**
Marit Boxum, The Netherlands
- 17:10-17:12 **Frontotemporal Alpha Power Is Reduced In People With ALS But Alpha Modulation Remains Intact**
Narin Suleyman, Ireland
- 17:12-17:14 **Global Taskforce On Genetic Counselling And Testing In ALS/MND: Developing Consensus-Based Guidelines**
Ammar Al-Chalabi, United Kingdom
- 17:14-17:20 Discussion

17:20-19:00 ENCALS RESEARCH FORUM – POSTERS SESSION

Thursday June 25th - Congress

08:30-10:00 INNOVATIVE PRECLINICAL MODELS:

BRIDGING MECHANISMS AND TRANSLATION

Moderators:

Andrea Malaspina (UCL Queen Square MND Centre, London, United Kingdom)

Sonia Alonso Martín (Biogipuzkoa, San Sebastián, Spain)

08:30-08:45 Plenary Speaker:

Jochen Weishaupt

(Universitäts und Rehabilitationskliniken Ulm (RKU), Ulm, Germany)

08:45-08:50 Discussion

08:50-09:00 Elucidating The Pathological Interplay Between Cytoskeletal Alterations And mRNA Metabolism In Profilin1-Mutant Human Motor Neurons

Christina Steffke, Germany

09:00-09:10 ALS Susceptibility Gene ARPP21 Assembles Into Dynamic RNA Granules And Drives TDP-43 Proteinopathy

Afra Aabdien, United Kingdom

09:10-09:20 Targeting The PP2A-AKT-GSK3 Axis In ALS: Implication Of FMRP

Benedetta Frizzi, Belgium

09:20-09:30 Dissecting The Mechanisms And Rescue Of Astrocyte Toxicity In Sporadic Amyotrophic Lateral Sclerosis (SALS)

Katie Bowden, United Kingdom

09:30-09:40 Dysregulated Skeletal Muscle Signaling And Extracellular Vesicle Cargo Disrupt Muscle-to-neuron Communication In ALS

Amaia Elicegui, Spain

09:40-09:50 TDP-43 Pathology Induces CD8 T Cell Activation Through Cryptic Epitope Recognition

Matteo Zanovello, United Kingdom

09:50-10:00 RIG-I Mediated Neuron-Specific IFN Type 1 Signaling In FUS-ALS Induces Neurodegeneration And Offers New Biomarker-Driven Individualized Treatment Options For (FUS-)ALS

Marcel Naumann, Germany

10:00-10:25 Coffee Break and Posters

10:25-10:30 Group photo

Thursday June 25th - Congress

10:30-11:40 EPIDEMIOLOGY AND PHENOTYPING

Moderators:

Elisabetta Pupillo (Mario Negri Institute for Pharmacological Research, Milano, Italy)

Alejandro Caravaca Puchades (Hospital Universitari de Bellvitge, Barcelona, Spain)

10:30-10:45 Plenary Speaker:

Mónica Povedano Panadés

(Hospital Universitari de Bellvitge – IDIBELL, Barcelona, Spain)

10:45-10:50 Discussion

10:50-11:00 The Risk Of MND In A Large Cohort Of Male UK Former Professional Footballers

Elisabetta Pupillo, Italy

11:00-11:10 The Multistep Pathogenic Hypothesis Of Amyotrophic Lateral Sclerosis Is Incompatible With The Epidemiological Data

Guglielmo Foffani, Italy

11:10-11:20 Examining The Age-Incidence Curves Of ALS Across European Register: The Multistep Hypothesis revisited

Robert McFarlane, Ireland

11:20-11:30 Exposome-Wide Association Study (ExWAS) In ALS

Laura van der Schoor, The Netherlands

11:30-11:40 Motor Function And Symptom Burden In Advanced ALS – ALS Functional Rating Scale Assessment Proximate To Death

Susanne Spittel, Germany

11:40-12:30 DEBATE

ARE WE READY TO REDEFINE ALS THROUGH PRECISION AND EARLY INTERVENTION?

Chair:

Orla Hardiman (Trinity College of Dublin, Ireland)

Plenary Speakers:

Andrea Calvo

(Università degli Studi di Torino and AOU Città della Salute e della Scienza di Torino Hospital, Turin, Italy)

Ammar Al-Chalabi

(Maurice Wohl Clinical Neuroscience Institute and King's College London, London, United Kingdom)

12:30-12:50 RAPID FIRE PRESENTATIONS II

Moderators:

Helene Blasco (University of Tours, France)

Raúl Juntas (Hospital Vall d'Hebron, Barcelona, Spain)

12:30-12:32 Large-Scale Exome Analyses Reveal Novel Rare Variant Contributions In Amyotrophic Lateral Sclerosis

Paul Hop, The Netherlands

Thursday June 25th - Congress

- 12:32-12:34 **Identity-By-Descent Analyses Reveals C9orf72 Discordance, Cryptic Relatedness, And Expanded ALS Pedigrees**
Ciara O'Donoghue, Ireland
- 12:34-12:36 **Genetic Architecture Of Familial ALS In The Netherlands**
Bi-Nan Wang, The Netherlands
- 12:36-12:38 **Exploring The Power To Detect Pathogenic Mutations Through Haplotype Analyses In Distantly Related patients with ALS**
Paul Beele, The Netherlands
- 12:38-12:40 **APOEε4 Homozygosity Accelerates The Onset And Progression Of ALS Neurodegeneration**
Sebastian A. Lewandowski, Sweden
- 12:40-12:42 **Integrated CSF–Blood Immune Profiling Reveals Immune Signatures Associated With Clinical Response**
Timothy Tree, United Kingdom
- 12:42-12:44 **Clustering On CSF Biomarkers And Clinical Parameters Reveals A Signature Of Neuroinflammation**
Manuela Basso, Italy
- 12:44-12:46 **Metabolic Signatures Of Ferritin And TDP-43 Co-Pathology Provide A Mechanistic Basis For Stratified Therapeutic approaches in ALS**
Holly Spence, United Kingdom
- 12:46-12:50 Discussion
- 12:50-13:50 Lunch Time and Posters
- 13:50-14:50 ALS AS A MULTISYSTEM DISORDER: BEYOND MOTOR NEURON DEGENERATION**
Moderators:
Caroline McHutchinson (University of Stirling, United Kingdom)
Juan I. López Carbonero (Hospital Clínico San Carlos, Madrid, Spain)
- 13:50-14:05 **Plenary Speaker:**
Teresa Salas Campos
(Hospital Universitario La Paz/Carlos III, Madrid, Spain)
- 14:05-14:10 Discussion
- 14:10-14:20 **Neuropsychological Sub-Phenotypes In Amyotrophic Lateral Sclerosis**
Barbara Poletti, Italy
- 14:20-14:30 **Quantifying Behavioral Changes In ALS: Longitudinal Trajectories And Functional Network 72 Correlates Of A Domain-Specific Behavioral Scale**
Laura Josephine Hagedorn, The Netherlands
- 14:30-14:40 **Cognitive Profiles In C9orf72 Families: Evidence For Nurture By Nature**
Annebel Michielsen, The Netherlands
- 14:40-14:50 **Somatosensory Neurological Soft Signs Associate With Executive Function In Unaffected Familial ALS Relatives Independent Of C9orf72 Status**
Sarah Darcy, Ireland

Thursday June 25th - Congress

14:50-15:15 RAPID FIRE PRESENTATIONS III

Moderators:

André Maier (Charité Universitätsmedizin Berlin, Germany)

Silvia Corrochano (Hospital Clínico San Carlos, Madrid, Spain)

14:50-14:52 **C9orf72 Repeat Expansion Affects Immune Response In A Xenografted Microglia Mouse Model**

Laura Fumagalli, Belgium

14:52-14:54 **A Distinct SPP1 Microglial Subset Initiates CD44-astrocyte Crosstalk In ALS**

Jianing Lin, Sweden

14:54-14:56 **Proteomic And Histological Profiling Of The ALS Visual Cortex Reveals Early Presynaptic Dysfunction And White Matter Atrophy**

Zsolt Laszlo, United Kingdom

14:56-14:58 **Novel TDP-43 Amyloid Polymorphs Uncover Aggregation Mechanisms In ALS**

Javier Oroz, Spain

14:58-15:00 **STMN2 Protein Depletion Via Translation Deficits And Stress Granules Independent Of TDP-43 Loss Of function**

Brittany Ellis, United Kingdom

15:00-15:02 **M6A-Dependent RNA Condensation Underlies FUS Autoregulation And Can Be Harnessed For ALS Therapy**

Vedanth Kumar, United Kingdom

15:02-15:04 **TDP-43 Dysfunction Disrupts Brain Cholesterol Homeostasis And Is Exacerbated By A High-Fat Diet**

Irene García-Toledo, Spain

15:04-15:06 **Patient-Derived Cortical Brain Organoids Model Key Pathological Features Of ALS**

Beatriz Fernandez-Muñoz, Spain

15:06-15:08 **CRISPR Kinome Screens In Human Motor Neurons Reveal Druggable Modulators Of TDP-43 Pathology**

Tania Atienzar, United Kingdom

15:08-15:10 **Disruption Of The Motor Neuron Translatome Is Disease-Specific In ALS And SMA But Converges On MCM5**

Hannah Smith, United Kingdom

15:10-15:15 Discussion

15:15-15:45 Coffee Break and Posters

Thursday June 25th - Congress

15:45-16:55 RETHINKING ALS PATHOGENESIS: EMERGING MOLECULAR PARADIGMS

Moderators:

Anna Sanchez Ávila (University of Sheffield, United Kingdom)

Ana C. Calvo Royo (Univ. Zaragoza, Spain)

15:45-16:00 Plenary Speaker:

Christine Vande Velde

(Université de Montréal, Montreal, Canada)

16:00-16:05 Discussion

16:05-16:15 Glial Phagocytosis As A Mechanism Of Synapse Loss In ALS

Zsolt Laszlo, United Kingdom

16:15-16:25 Distinct Routes To Abnormal TDP-43 Oligomerisation In ALS-C9 And Sporadic ALS

Anna Sanchez Avila, United Kingdom

16:25-16:35 Longitudinal Single-Cell RNAseq Reveals Immune Lineage Diversion And Accelerated Senescence As Drivers Of ALS Progression And Neurodegeneration

Oriol Dols-Icardo, Spain

16:35-16:45 Virotrap-Based Interactomic Profiling Reveals Novel HDAC6 Interactors With Therapeutic Relevance To ALS

Dufie Strubbe, Belgium

16:45-16:55 Immune Stimulation Exacerbates Cell Autonomous Microglial Dysfunction In A Stem Cell Model Of TBK1-Associated ALS-FTD

Owen M. Peters, United Kingdom

16:55-18:10 ENCALS RESEARCH FORUM – POSTERS SESSION

Friday June 26th - Congress

09:00-10:15 CLINICAL TRIALS, STRATIFICATION AND CLINICAL OUTCOMES

Moderators:

Ciara O'Donoghue (Trinity College, Dublin, Ireland)

Javier Mascías Cadavid (Hospital Carlos III, Madrid, Spain)

09:00-09:15 Plenary Speaker:

Ruben van Eijk

(University Medical Center Utrecht, Utrecht, The Netherlands)

09:15-09:20 Discussion

09:20-09:30 Introducing A Standardized Protocol Template For Early-Efficacy Trials In ALS: Improving Phase 2-to-3 Decision-Making (MAGNET-II)

JWJ Van Unnik, The Netherlands

09:30-09:40 Towards Regulator-Aligned Synthetic Placebo Construction In ALS: A Prespecified And Externally Validated PRO-ACT Framework

Mandy Miresmaeili, United Kingdom

09:40-09:50 Efficacy And Tolerability Of-Hydroxybutyrate In Patients With Amyotrophic Lateral Sclerosis (KETO-ALS) - A Randomised, Placebo-Controlled, Double-Blind Study

Christine Herrmann, Germany

09:50-10:00 Salivary Dim-Light Melatonin Onset Predicts Functional Decline And Survival In Early Amyotrophic Lateral Sclerosis

Alessandro Bombaci, Italy

10:00-10:15 Discussion

10:15-10:45 YOUNG INVESTIGATOR AWARD

10:45-11:15 Coffee Break and Posters

11:15-12:40 ADVANCED CLINICAL PHENOTYPING USING NEW TECHNOLOGIES

Moderators:

Blaž Koritnik (Ljubljana University Medical Centre, Slovenia)

Marta Vallejo de Frutos (Heriot-Watt University, Edinburgh, United Kingdom)

11:15-11:27 Plenary Speaker:

Alejandro Caravaca Puchades

(Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain)

11:27-11:30 Discussion

11:30-11:42 Plenary Speaker:

Nicola Ticozzi

(Istituto Auxologico Italiano, University of Milan, Milan, Italy)

11:42-11:45 Discussion

11:45-11:55 The Precision ALS Research Platform

Ronan McDonnell, Ireland

Friday June 26th - Congress

- 11:55-12:05 **Machine Learning Validation Of Gene Expression-Based ALS Subtypes Across Brain And Blood Tissues**
Esteban Alberto Gomez Cifuentes, United Kingdom
- 12:05-12:15 **Symptom-Based Phenotype Discovery In Motor Neuron Disease Using Natural Language Processing Of Electronic Health Records**
Yusuf Abdulle, United Kingdom
- 12:15-12:25 **Red Flags For The Early Diagnosis Of Amyotrophic Lateral Sclerosis: Machine-Learning Algorithms Applied To Data From A Referral Center**
Enrico Matteoni, Italy
- 12:25-12:35 **Progression Of ALS Milestones Differs Across Disease Phenotypes**
Rosario Vasta, Italy
- 12:35-12:45 **Linking Clinical And Laboratory Electrophysiology Studies For Patient-Stratified Research In MND**
Daniel de la Fuente, United Kingdom
- 12:45-13:15 CLOSING SESSION: THE ROAD AHEAD IN ALS**
- Meeting Summary
 - Rapid Fire and Poster prizes
 - Welcome to Lübeck

ENCALS

European Network to Cure ALS

SECOND SECTION



Industry Sponsored session

AL-S PHARMA

AL-S Pharma Symposium
Tuesday, June 23rd
14.00-16.30
Buenos Aires – Havana – Mexico Room



Ferrer-Prilenia Symposium
Wednesday, June 24th
11.45-13.00
Buenos Aires – Havana – Mexico Room



Italfarmaco Symposium
Wednesday, June 24th
11.30-13.00
Caracas – Bogotá Room

AL-S PHARMA'S ENCALS 2026 INDUSTRY SYMPOSIUM

AL-S PHARMA

Tuesday, June 23th

14.00-16.30

Buenos Aires–Havana–Mexico Room

Format: Three 20-25-minute talks with 5-10-minute Q&A for each,
followed by panel discussion and Q&A (45 minutes)

BEYOND “SPORADIC” ALS: GENETICS, BIOMARKERS, AND THE MISFOLDED SOD1 PATHWAY

Symposium Description

This symposium will bring together internationally recognized leaders in ALS research to examine how advances in disease biology are reshaping clinical investigation and therapeutic development. Designed for neurologists, physician-scientists, clinical trialists, and industry professionals in drug development, the session will connect emerging insights in genetic architecture, biomarker interpretation, and protein misfolding biology to the practical realities of ALS diagnosis, stratification, and trial design. The symposium will open with a contemporary reappraisal of so-called sporadic ALS, challenging the traditional familial/sporadic divide and highlighting a more nuanced view of genetic contribution and disease architecture; it will then turn to neurofilament biomarkers in ALS clinical trials, focusing on what these markers have taught us over time, where they are most useful today, and how they should be interpreted in the context of therapeutic studies; and it will conclude with a deep dive into the misfolded SOD1 pathway, addressing its biologic significance, mechanistic implications, and relevance for biomarkers and targeted therapies.

Featured Speakers and Talk Titles

1. Prof. Ammar Al-Chalabi, PhD, FRCP, FMedSci

Beyond “Sporadic” ALS: Rethinking Genetic Architecture and Disease Classification

- Reassessing the limitations of the traditional familial/sporadic divide in ALS
- Exploring how rare variants, polygenic risk, penetrance, and gene–environment interplay may shape sporadic disease and future precision trial design

2. Prof. Dame Pamela Shaw, DBE, MBBS, MD, FRCP, FAAN, FANA, FAAAS

Neurofilament Biomarkers in ALS Clinical Trials: Then, Now, and How to Interpret Them

- Tracing the evolution of neurofilament biomarkers from research tools to established components of ALS clinical development
- Examining their current utility and the key challenges in interpretation across prognosis, stratification, pharmacodynamic assessment, and trial design

3. Prof. Philip Van Damme, MD, PhD

The Role of SOD1 in ALS

- Reviewing the lessons learned from SOD1-ALS
- Discussing how misfolded SOD1 could play a role in the absence of SOD1 mutations

Panel Discussion: Translating ALS Biology into Better Trials

Moderator: Angela Genge, MD, FRCP(C), eMBA, chief medical officer, AL-S Pharma AG
Panelists: Prof. Leonard van den Berg, PhD, Prof. Andrea Malaspina, MD, PhD,
Prof. Julian Grosskreutz, MD

A moderated panel discussion will follow the presentations, bringing together the speakers and invited experts to discuss how emerging insights in ALS genetics, biomarker interpretation, and misfolded protein biology can be translated into better trial design, patient stratification, and therapeutic development.

ADVANCING NEUROPROTECTIVE CARE IN RARE DISEASES

Strength Through Partnership

Wednesday, June 24th

11.30-13.00

Buenos Aires - Havana - Mexico Room



11:30 - 11:45 PREVAiLS Phase 3 update:

Biological rationale, study design and implications for patient-relevant outcomes in ALS

MAs part of TRICALS Satellite Meeting

11.45-13.00 From Disease Burden to Meaningful Benefit in ALS:

Aligning Symptom Relevance, Management, and Novel Trial Endpoints

Ferrer-Prilenia Satellite Meeting

ALS MILESTONES AND TOMORROW MEDICINE: A JOURNEY FROM 1990 TO THE FUTURE

Wednesday, June 24th

11:30 - 13:00

Caracas-Bogota Room



Chairman:

The European ALS Community's Commitment: Learning from the Past to Shape the Future.

Pr. Philippe Corcia, Tours (France)

Speakers:

Milestones in ALS over the last 30 years

Pr. Julian Grosskreutz, Luebeck (Germany)

The future of ALS diagnosis

Pr. Mónica Povedano, Barcelona (Spain)

The future of ALS care

Pr. Nicola Ticozzi, Milano (Italy)

Advancing Neuroprotective Care in Rare Diseases

Strength Through Partnership

Ferrer and Prilenia, are committed to changing the lives of people with neurodegenerative diseases. United to accelerate innovative new therapies for patients, Ferrer brings expertise in rare neurological diseases, while Prilenia brings experience with pridopidine and neurodegenerative diseases. Ferrer is the highest-rated pharma B Corp, reinvesting ~50% of profits in social and environmental initiatives. Prilenia is driven by unwavering commitment to scientific excellence in developing transformative medicines for neurodegenerative diseases.

Join the Scientific Exchange

Satellite Meetings

Location: BUENOS AIRES - HAVANA – MEXICO Room

📅 Wednesday, June 24th

11:30 - 11:45

PREVAiLS Phase 3 update: Biological rationale, study design and implications for patient-relevant outcomes in ALS.

As part of TRICALS Satellite Meeting

11:45 - 13:00

From Disease Burden to Meaningful Benefit in ALS: Aligning Symptom Relevance, Management, and Novel Trial Endpoints.

Ferrer-Prilenia Satellite Meeting



Prof. Leonard van den Berg, MD, PhD

UMC Utrecht, The Netherlands



Valérie Berlaumont, PhD

ALS Patient, member of ALS Liga and EUPALS



Assoc. Prof. Andrea Calvo, MD, PhD

Università degli Studi di Torino, Italy



Assoc. Prof. Ruben van Eijk, MD, PhD

UMC Utrecht, The Netherlands



Prof. Caroline Ingre, MD, PhD

Karolinska Institutet and Karolinska University Hospital, Sweden



PREVAiLS (Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS)
a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in ALS

📅 **Poster #471**
➔ Exhibition area

📅 Wednesday, June 24th
🕒 17:20h - 19:00h

🍽️ **Session: ENCALS RESEARCH FORUM – POSTERS SESSION**



QurAlisTM

Neuro Pioneers on a Quest to Cure

QurAlis is a proud sponsor of
ENCALS 2026

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases.



www.quralis.com



MAKING BREAKTHROUGHS HAPPEN

We are proud to sponsor
the 2026 ENCALS meeting



May 2026. Biogen-287051

AXONIA

ACCREDITED WEBINAR SERIES

Meet Axonia, a four-part expert-led webinar series
on rare neurodegenerative diseases

New WEBINAR! HIDDEN SIGNS: ALS and the Motor Neuron Spectrum

- Available from May 6th – 18:00h (GMT+1)
- Live session + later on-demand access with short video capsules for flexible learning

Webinar 2

xpeer | AXONIA



ACCREDITED
BY THE UEMS



Prof. Thomas Meyer

Neurologist specialized in ALS
and neuromuscular disorders




Prof. Leonard van den Berg

Neurologist specialized in ALS and
motor neuron diseases

Live on xpeer

DESIGNED FOR CLINICAL IMPACT:

- **Evidence-informed content** distilled into a clear, practical format
- **Accredited learning** for continuous professional development
- Flexible access: **live interaction + on-demand replay**
- Content relevant for **neurologists, GPs, and multidisciplinary teams involved in ALS care**
- **Real clinical cases**



>400 HCPs
already joined
AXONIA



APP ENCALS MEETING 2026

Everything you need
is right in your pocket.


Scan the QR code
to download the official app.

**DOWNLOAD NOW
AND DON'T MISS A BEAT!**

1. DOWNLOAD TORRES PARDO EVENTS



2. CLICK HERE



GOLD SPONSORS



SILVER SPONSORS



STANDARD SPONSORS



SYMPOSIA SPONSORS



ENCALS

European Network to Cure ALS



Certificates of attendance and CME credits

You must scan your badge when entering and leaving the venue.

All certificates will be sent by email when the congress finishes.

With the Support of

